Do you providecompanies with innovative solutions to improve supply chain efficiency?
In addition to our primary packaging for solid doses, unit dose packaging and secondary packaging services, we also provide integrated supply chain services, such as postponement packaging or late-stage customisation to help our customers cope with small-scale market requirements.
In June 2017, the FDA announced that it will delay the active enforcement of the Drug Supply Chain Security Act (DSCSA) for pharmaceutical manufacturers to November 2018 due to industry-wide concerns that many members of the pharmaceutical supply chain are behind in implementing serialization systems and processes.
The numbers are daunting – 15% of the global population suffers from hearing loss, including a significant number of children, teenagers, and the elderly. Hearing loss presents a growing public health problem, due to ageing and an urban way of life that features excessive noise exposure.
The average cost of bringing a new drug to market is $2.6 billion, according to a 2014 report published by Tufts Center for the Study of Drug Development. This is a rise of 145%, adjusted for inflation, compared to just a decade earlier and is driven in part by the increasing complexity of clinical trials.
Biotechnology and pharmaceutical companies within the United States and Europe face an increasing number of hurdles when undertaking clinical trials within their own country or region; problems such as over saturated patient pools, difficulties meeting and maintaining enrollment numbers, increasing costs and lengthy time delays.
Interview & Whitepapers
News & Press Releases
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).
A New Year report from CPhI forecasts 2018 will be a transformative year for Japanese pharma as the market evolves towards growth in generics, biosimilars and increased internationalisation.
A new serialisation implementation partner has formed to assist the increasing number of companies needing to meet the data requirements of looming global regulation changes.
FuturaGene, a wholly owned subsidiary of Suzano Pulp and Paper, and Australia’s Commonwealth Scientific and Industrial Research Organisation (CSIRO), are pleased to announce that a patent has been issued in Brazil to CSIRO, which covers the downregulation of the expression of plant target genes or other target genes, including genes of insect pests and disease agents.
Ziath announced it will showcase its new, cost-effective 2D barcode rack scanner, the DataPaq™ Mirage, at SLAS2018 (3–7 February 2018, San Diego, CA).
Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the appointment of Frank Thomas to the newly created position of chief financial officer and chief business officer.
Inovio Pharmaceuticals, Inc. and the Parker Institute for Cancer Immunotherapy have entered into a clinical collaboration agreement that provides for Inovio and the Parker Institute to undertake clinical evaluation of novel combination regimens within the field of immuno-oncology.
STORM Therapeutics, the leading drug discovery company focused on small molecule therapies modulating RNA modifying enzymes, announced that it has raised an additional GBP4 million of funding from Taiho Ventures, LLC the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd.
Myriad Genetics, Inc. , a leader in molecular diagnostics and personalized medicine, announced that AstraZeneca will use the Company’s myChoice® HRD Plus in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza and Avastin.
Biohaven Pharmaceutical Holding Company Ltd. and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced that the U.S. FDA has notified the Company that it may proceed with its clinical investigation of BHV-5000.
BioNTech Diagnostics GmbH is announcing new results from two studies on the MammaTyper® test which were presented at the Breast Cancer Symposium in San Antonio in December.1,2
Adverum Biotechnologies, Inc , a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced the dosing of the first patient in the ADVANCE Phase 1/2 clinical trial of ADVM-043 for alpha-1 antitrypsin (A1AT) deficiency.
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.
Orchard Therapeutics , a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, announced the opening of a second facility for technical operations in the San Francisco Bay Area.
Batavia Biosciences announces the expansion of its viral vector process development facilities in the USA and its GMP clean room facilities in the Netherlands to accommodate the increasing market demand.
New from Watson-Marlow Fluid Technology Group (WMFTG) is the Flexicon PF7 peristaltic tabletop aseptic liquid filling machine optimised for operation in GMP regulated industries such as biotechnology, pharmaceutical and diagnostics.
Multi Packaging Solutions, (MPS), a business of WestRock Company and a leader in value-added print and packaging solutions for the healthcare, branded consumer and multi-media markets, in partnership with Smartglyph, a UK technology business, can now offer customers the ability to allow their packs to ‘talk’ to the consumer.